Benign prostatic hyperplasia (BPH), Acute urine Retention (AUR)
Conditions
Interventions
Two groups:Alfuzosin GITS 10 mg vs placebo for two years
Sponsors
Division of Urology, Department of Surgery, the Chinese University of Hong Kong
Eligibility
Sex/Gender
Male
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50 or above; 2. Presented with first episode of AUR due to BPH with residual urine of 500 - 1500ml; 3. Successful TWOC after use of Alfuzosin GITS.
Exclusion criteria
Exclusion criteria: 1. Previous history of TURP or other form of invasive therapy for benign prostate hyperplasia; 2. Patient suspected or confirmed to have carcinoma of prostate; 3. Use of alpha blockers within recent 6 months; 4. Use of phytotherapy or 5-alpha reductase inhibitors within recent 6 months; 5. Clot retention secondary to haematuria of any cause; 6. Patients with depressive illness on medication, extra-pyramidal disorders, neurological disease; 7. Patients with unstable angina, myocardial infarction, transient ischaemic attacks, cerebrovascular accident or congestive cardiac failure during the previous 6 months; 8. Patients contraindicated for alfuzosin: (1) Known hypersensitivity to alfuzosin; (2) Orthostatic hypotension; (3) Hepatic insufficiency. 9. Poor premorbid state
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to compare alfuzosin GITS 10 mg daily with placebo, in delaying or avoiding invasive therapy for BPH on long term follow up of Hong Kong Chinese males patients achieving a successful TWOC after AUR secondary to BPH.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective is to investigate the safety of alfuzosin GITS and also predicting factors for recurrent AUR.; | — |
Countries
China
Contacts
Public ContactNg Chi Fai
Outcome results
None listed